RACIAL VARIATION IN MYELOSUPPRESSION HOSPITALIZATIONS AMONG INFLAMMATORY BOWEL DISEASE PATIENTS

UTHEalth
The University of Texas

Health Science Center at Houston

School of Public Health

Ryan Suk¹, Ashish A. Deshmukh¹, Kalyani B. Sonawane¹, Jihee Song², Jinhai Huo²

¹The University of Texas Health Science Center at Houston; ²University of Florida

Background

Thiopurine therapy is used as a standard of care in inflammatory bowel disease (IBD), but it might cause fatal myelosuppressive adverse events that require hospitalization. While racial disparities in IBD treatment and management has been well-documented in the US, whether these racial disparities have caused high risk of myelosuppression hospitalizations in minority population is still unknown.

Methods

- We used Nationwide Inpatient Sample (NIS) from 2003 to 2014.
- We identified patients who were hospitalized with a primary diagnosis of IBD, or IBD-related complications.
- Primary outcomes: The prevalence of hospitalizations from myelosuppressive adverse events (neutropenia/leukopenia, drug-induced anemia, or thrombocytopenia) among the IBD patients. The urgent admissions among the myelosuppression hospitalizations.
- We used multivariable logistic regression to examine the association between sociodemographic and hospitallevel factors and the risk of primary outcomes.

Results

- We found significantly higher odds of being hospitalized for the myelosuppression among the non-Hispanic blacks (aOR=1.3; 95% CI [1.2-1.4]), Hispanics (aOR=1.6; 95% CI [1.4-1.7]), and Asian/Pacific Islanders (aOR=2.3; 95% CI [1.9-2.8]) compared to the non-Hispanic whites.
- Among those patients diagnosed with myelosuppression, the non-Hispanic blacks (aOR=1.7; 95% CI [1.2-2.3]) and Hispanics (aOR=1.6; 95% CI [1.1-2.2]) had significantly higher odds of getting admitted urgently compared to the non-Hispanic whites.

	Myelosuppression Hospitalizations Adjusted Odds Ratios (95% CI)	Urgent admission Adjusted Odds Ratios (95% CI)		Myelosuppression Hospitalizations Adjusted Odds Ratios (95% CI)	Urgent admission Adjusted Odds Ratios (95% CI)
White Black Hispanic Asian/PI Others	Ref 1.3a (1.2 to 1.5) 1.5a (1.4 to 1.6) 2.1a (1.7 to 2.6) 1.4a (1.2 to 1.6)	Ref 1.9a (1.4 to 2.5) 1.6a (1.1 to 2.2) 1.0 (0.6 to 1.8) 0.6a (0.4 to 0.9)	Neighborhood median house income 1st quartile 2nd quartile 3rd quartile 4th quartile	(continued) Ref 1.1 ^a (1.01 to 1.2) 1.1 ^a (1.1 to 1.2) 1.2 ^a (1.1 to 1.3)	(continued) Ref 1.0 (0.8 to 1.4) 1.2 (0.9 to 1.6) 0.9 (0.7 to 1.3)
ge group 0-20 21-30 31-45 46-64 ≥65	Ref 0.7a (0.6 to 0.8) 0.5a (0.5 to 0.6) 0.5a (0.4 to 0.5) 0.6a (0.5 to 0.7)	Ref 1.4a (1.1 to 1.8) 1.2 (0.9 to 1.6) 1.2 (0.9 to 1.6) 1.4 (0.9 to 2.1)	Hospital regions West Northeast Midwest South	Ref 0.7a (0.6 to 0.8) 0.7a (0.6 to 0.8) 0.8a (0.7 to 0.8)	Ref 1.1 (0.8 to 1.6) 0.6 ^a (0.4 to 0.9) 0.5 ^a (0.4 to 0.7)
Female Male rimary payer Private Medicare Medicaid	Ref 0.9a (0.8 to 0.9) Ref 0.8 (0.7 to 0.9) 1.0 (0.9 to 1.1)	Ref 1.0 (0.9 to 1.2) Ref 1.3 (0.9 to 1.8) 1.4a (1.1 to 1.8)	Charlson comorbidity 0 1 2 ≥3 IBD-related	Ref 0.6a (0.6 to 0.7) 0.5a (0.5 to 0.6) 0.6a (0.6 to 0.7)	Ref 1.4a (1.1 to 1.7) 1.3 (0.9 to 1.8) 2.5a (1.6 to 3.8)
Self-pay No Charge Other	1.1 (1.0 to 1.2) 1.3 ^a (1.1 to 1.7) 1.2 ^a (1.1 to 1.4)	3.6 ^a (2.2 to 5.9) 8.8 ^a (1.6 to 48.4) 0.8 (0.5 to 1.3)	surgery Yes No	Ref 2.1 ^a (1.9 to 2.4)	Ref 15.0ª (11.5 to 19.7)

- Besides the racial factors, primary payer type and IBD-related surgery status during hospitalization were the biggest associated factors.
- The patients with Medicaid (aOR=1.4) self-pay (aOR=3.6) and no charge (aOR=8.8) had significantly higher odds of getting admitted urgently compared to those with private insurance (statistically significant).
- The patients who did not undergo IBD-related surgery had significantly higher odds of myelosuppression hospitalization (aOR=2.1) and getting urgently admitted (aOR=15.0) compared to those who underwent IBD-related surgery during the hospital stay (statistically significant).

Conclusion

- The risk of myelosuppression hospitalizations is greater in minority patients diagnosed with IBD in the US population than in non-Hispanic whites.
- Future studies are needed to investigate factors that are driving these racial variations.

Contact: ryan.suk@uth.tmc.edu